Abstract:Dyslipidemia is an important risk factor for atherosclerotic cardio-cerebro-vascular diseases. Clinical studies have shown that statins could signifi cantly reduced cardiovascular events by reducing the level of low density lipoprotein cholesterol. However, it is difficult to achieve standard serum lipid levels recommended by guideline even with high doses of statins. For high-risk groups with diabetes or metabolic syndrome, the combination of statins and fibrates, niacin, cholesterol absorption inhibitors would be a preferable alternative in clinical.